Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Atrovent®

Study type: Observational

Funder types: Industry

Identifiers

NCT02236715

244.2493

Details and patient eligibility

About

Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice

Enrollment: 1,039 patients

Sex: All

Ages: 30+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Primarily patients of both gender, older than 30 years, who suffer from chronic obstructive airways disease
• Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion

Exclusion criteria

• Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® unit dose vial 500 µg

Trial design

1,039 participants in 1 patient group

Chronic Obstructive Airways Disease

Treatment:

Drug: Atrovent®